OSLO, Norway, Feb. 11, 2021 /PRNewswire/ -- Targovax ASA, a
clinical stage immuno-oncology company developing immune activators
to target hard-to-treat solid tumors, will host a virtual Capital
Markets Day for investors, analysts and journalists on 18 February 2021 at 2:30
PM CET. The Capital Markets Day will feature presentations
from executive management and Alexander Shousthari, Medical
Oncologist at Memorial Sloan Kettering Cancer Center, and will be
webcast live and accessible at
https://www.targovax.com/en/capital-markets-day-2021/
Based on the strong clinical data that are now generated on
ONCOS-102, Targovax has a solid fundament to move into late stage
clinical development. We also have a broader pipeline of
preclinical assets that could create a broader horizon of
opportunities in the future. The Capital Markets day will feature
presentations updating the market on these aspects.
The agenda will be as follows:
Agenda &
speakers
|
2:30-2:40
PM
|
Welcome
|
Øystein Soug, CEO,
Targovax
|
2:40-3:25
PM
|
Anti-PD1 refractory
melanoma
|
Alexander N.
Shoushtari, MD
|
3:25-3:45
PM
|
ONCOS-102 development
program
|
Magnus Jäderberg,
CMO, Targovax
|
5 minutes
break
|
3:50-4:05
PM
|
Immune
activation
|
Victor Levitsky, CSO,
Targovax
|
4:05-4:15
PM
|
Preclinical pipeline
update
|
Victor Levitsky, CSO,
Targovax
|
4:15-4:25
PM
|
4Q update
|
Torbjørn Furuseth,
CFO, Targovax
|
4:25 PM
|
Closing
remarks
|
Øystein Soug, CEO,
Targovax
|
The presentations will be made available on the company's
website after the end of the meeting. Questions can be submitted
through the webcast throughout the event.
Biography:
Dr. Alexander Shoushtari
is renowned expert in melanoma, with a research focus on uveal and
mucosal melanomas. He is part of several immunotherapy trials at
MSKCC and Dr. Alexander Shoushtari
is the Principal Investigator on the ONCOS-102 phase I trial in CPI
refractory advanced melanoma. He is a member of the research team
of Dr. Jedd Wolchok, MD, PhD, Chief,
Melanoma and Immunotherapeutics Service at the Memorial Sloan
Kettering Cancer Center.
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz - LHA Investor
Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/agenda-for-targovax-s-capital-markets-day-18-february-2021,c3284456